<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Who should be tested for tuberculosis infection (latent TB)?</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Who should be tested for tuberculosis infection (latent TB)?</h1>
<div class="graphic"><div class="figure"><div class="ttl">Who should be tested for tuberculosis infection (latent TB)?</div><div class="cntnt"><table cellspacing="0"><tbody> <tr> <td class="subtitle1_single">Individuals with increased risk of new TB infection</td> </tr> <tr> <td class="indent1"> <ul> <li>Close contacts of patients with untreated respiratory TB disease*</li> <li>Casual contacts of patients with untreated respiratory TB disease*</li> <li>People who use illicit drugs</li> <li>Residents or employees of a homeless shelter or correctional facility</li> <li>Health care workers in some circumstances<sup>¶</sup></li> </ul> </td> </tr> <tr> <td class="subtitle1_single">Individuals with increased risk of reactivation<sup>Δ</sup></td> </tr> <tr> <td class="subtitle2_single">High risk (test all patients)</td> </tr> <tr> <td class="indent1"> <ul> <li>HIV infection (any stage of illness)</li> <li>Transplant, chemotherapy, or other major immunocompromising condition</li> <li>Lymphoma, leukemia, head and neck cancer</li> <li>Abnormal chest radiograph with apical fibronodular changes typical of healed TB (not including granuloma)</li> <li>Silicosis</li> <li>Renal failure (requiring dialysis)</li> <li>Treatment with TNF-alpha inhibitors</li> </ul> </td> </tr> <tr> <td class="subtitle2_single">Moderate risk (test patients in groups with increased prevalence of TBI)<sup>◊</sup></td> </tr> <tr> <td class="indent1"> <ul> <li>Diabetes mellitus</li> <li>Systemic glucocorticoids (≥15 mg/day for ≥1 month)<sup>§</sup></li> </ul> </td> </tr> <tr> <td class="subtitle2_single">Slightly increased risk (test patients in groups with increased prevalence of TBI)<sup>◊</sup></td> </tr> <tr> <td class="indent1"> <ul> <li>Underweight (&lt;85% of ideal body weight); for most individuals, this is equivalent to BMI ≤20</li> <li>Smoking cigarettes (≥1 pack/day)</li> <li>Chest radiograph with solitary granuloma</li> <li>Individuals born in or former residents of countries with high incidence of TB disease (<strong>without</strong> other risk factors listed above)<sup>¥</sup></li> </ul> </td> </tr> </tbody></table></div><div class="graphic_lgnd"><p>Only those who would benefit from treatment should be tested, so a decision to test presupposes a decision to treat if the test is positive. Individuals with very low likelihood of TBI should not be tested routinely, as the yield of testing is low and the likelihood of a false-positive test becomes more important.</p>
<p>Local epidemiologic patterns and risk groups may vary; consult local or state health departments for more information about populations with increased prevalence of TB infection in the local community.</p>
The approach to TBI testing should be individualized in older patients at lower risk of reactivation. The relationship between the risk of adverse events and increasing age is well documented for isoniazid. Thus far, data are insufficient to determine appropriate age thresholds for TBI testing if individuals with a positive test are treated with a shorter rifamycin-based regimen. Until further data on the age-related risks of adverse events with these regimens are available, it is reasonable to adhere to the same cautions as for isoniazid.</div><div class="graphic_footnotes"><p>TB: tuberculosis; TBI: TB infection; TNF: tumor necrosis factor; BMI: body mass index; CDC: United States Centers for Disease Control and Prevention; TST: tuberculin skin test.</p>
<p>* Close contacts are defined by the CDC as individuals with at least 4 hours of contact per week. This includes those living in the same household or frequent visitors to the house; it may also include contacts at work or school. Casual contacts are defined by the CDC as individuals with less than 4 hours of contact per week. This may include health care workers and/or contacts at work or school.</p>
<p>¶ In regions with low TB incidence rate, health care workers in facilities with low TST conversion rate need not undergo routine serial TB screening. Serial TB screening may be reasonable for HCWs at increased risk for occupational exposure to TB (such as pulmonologists or respiratory therapists) or for health care workers in certain settings (such as emergency departments). Refer to the UpToDate topic on diagnosis of TBI for further discussion.</p>
<p>Δ An individual with a false-negative test resulting from faded immune memory who then receives immunosuppression (such as a TNF inhibitor) may be at high risk of reactivation disease. Such individuals warrant a single test if interferon-gamma release assay is used; however, use of the TST warrants a two-step test.</p>
<p>◊ In general, groups with increased TBI prevalence include homeless individuals, injection drug users, contacts of patients with TB disease, and foreign-born individuals who immigrated as adults from countries with TB incidence &gt;100/100,000 (this includes most countries in Africa and Asia, many countries in Eastern Europe, Central America and South America, plus Haiti and the Dominican Republic).</p>
<p>§ The CDC recommends skin testing for all patients in this category. However, population-based studies demonstrate that the relative risk for development of TB disease in this category is moderate (2 to 4 times that of healthy individuals). Therefore, an age cutoff of ≤65 is indicated, so that potential risks of isoniazid toxicity in older adult patients do not outweigh potential benefit. (Refer to the separate UpToDate table summarizing relative risk for development of TB disease).</p>
¥ Individuals born in or former residents of countries with high TB incidence (&gt;100/100,000) are an additional category of individuals with increased prevalence of TB infection. In the United States and the United Kingdom, guidelines favor TBI testing for such individuals; in Canada, guidelines favor TBI testing only for groups within the immigrant population who have additional risk factors for progression to TB disease.</div><div id="graphicVersion">Graphic 74584 Version 13.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
